Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Atlassian Corporation PLC — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Atlassian Corporation PLC trades at $85.4 (market cap $22.43B). The key difference: Atlassian Corporation PLC is far larger — about 5× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| ACAD | TEAM | |
|---|---|---|
Market Cap | $4.49B | $22.43B |
Sector | Health | Technology |
52-Week High | $28.06 | $220.89 |
52-Week Low | $20.06 | $57.15 |
Enterprise Value | $3.69B | $22.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Atlassian (TEAM) trades at $88.39, up 5.43% with bullish technical signals despite negative profitability metrics. The stock shows strong revenue growth from $2.8B in 2022 to $5.2B in 2025, though net losses persist. Recent earnings beats and cloud revenue momentum of 29% in Q3 FY26 support optimism. Analyst consensus is strongly bullish with 30 buy ratings and a $120.29 price target, representing 36% upside potential.
The outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent losses, high valuation multiples, and competitive pressures. With improving margins and strong institutional support, TEAM offers growth exposure but requires tolerance for current unprofitability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
